Pernix Therapeutics (PTX) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Wall St set for muted open as tech stocks take a breather
- Oil slips on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailPernix Therapeutics (NASDAQ: PTX) reported Q4 EPS of $0.25, $0.07 better than the analyst estimate of $0.18. Revenue for the quarter came in at $53 million versus the consensus estimate of $52.7 million.
For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RXO shares soar as C.H. Robinson announces $5.8B cash and stock buyout
- S&P Global (SPGI) PT Lowered to $531 at Mizuho
- KeyBanc's Preview of 'Biggest Potential Beats in Life Science'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
